| Previous Close | 149.37 |
| Open | 149.71 |
| Bid | 149.64 x 100 |
| Ask | 150.87 x 200 |
| Day's Range | 149.57 - 150.30 |
| 52 Week Range | 120.75 - 150.30 |
| Volume | 85,078 |
| Avg. Volume | 117,193 |
| Net Assets | 19.31B |
| NAV | 147.20 |
| PE Ratio (TTM) | N/A |
| Yield | 1.00% |
| YTD Return | 10.95% |
| Beta (3y) | 1.07 |
| Expense Ratio (net) | 0.07% |
| Inception Date | 2004-01-26 |
- Zacks•2 days ago
Hot Areas of Last Week and Their ETFs
Hopes for Trump's tax reforms, abating North Korea fears, lower-than-expected damage from Hurricane Irma and record stock market highs rekindled the love for U.S. equity ETFs last week.
- ETF Trends•5 days ago
Small-Cap ETFs for a More Risk-On Investor
Small-capitalization stock investors were defensive going into the 2017, but they have quickly changed their tune, turning to more growth-weighted smaller company picks. Investors can also gain diversified ...
- Market Realist•12 days ago
Nuplazid for Long-Term Care: Revenue Driver for Acadia?
Acadia Pharmaceuticals (ACAD) plans to focus on long-term care (or LTC) facilities to boost Nuplazid’s adoption in the Parkinson’s disease (or PD) psychosis indication.
